Johnson & Johnson Reports $504M Biotech Portfolio in 13F Amendment
JOHNSON & JOHNSON
Subscribe to track JNJ
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Johnson & Johnson Reports $504M Biotech Portfolio in 13F Amendment
Company: Johnson & Johnson (JNJ) Form: 13F-HR/A (Restatement) | Filed: 2026-03-18 Significance: Low (Strategic Portfolio Update)
Manager: Johnson & Johnson Innovation - JJDC, Inc. Report Period: 09-30-2025
Portfolio Overview: • Total Value: $503,922,707 • Holdings Count: 20 Companies • Focus: Biotechnology & Pharmaceutical Preparations
Top Holdings (by Value): • Protagonist Therapeutics: ~$162.7M • Nanobiotix S.A.: ~$106.2M • MeiraGTx Holdings: ~$54.7M • Rapport Therapeutics: ~$53.0M
Key Insight: This amendment restates J&J's strategic venture capital holdings. While the $504M value is negligible relative to J&J's $582B market cap (<0.1%), it highlights key strategic interests in gene therapy and immunology sectors.
Market Context: J&J continues to maintain significant minority stakes in development-stage biotech partners despite broader market volatility.
Comprehensive Analysis
SEC Filing Analysis: Johnson & Johnson (JNJ)
Executive Summary
- Trading Significance: Low
- Key Takeaway: Johnson & Johnson filed an amendment to its 13F holdings report, disclosing a $504M strategic portfolio focused on small-cap biotechnology companies.
- Market Impact: Neutral for JNJ stock; potentially significant for the specific biotech companies held in the portfolio.
Company Information
| Field | Value |
|---|---|
| Company | Johnson & Johnson |
| Ticker Symbol | JNJ |
| CIK | 0000200406 |
| Industry | Pharmaceutical Preparations |
Insider/Manager Information
| Field | Value |
|---|---|
| Name | Johnson & Johnson |
| CIK | 0000200406 |
| Type | Institutional Investment Manager |
| Relationship | Strategic Investor (via JJDC, Inc.) |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 13F-HR/A (Amendment) |
| Report Period | 2025-09-30 |
| Transaction Code | N/A (Holdings Report) |
| Security Type | Various Public Equities |
| Total Holdings Value | $503,922,707 |
| Holdings Count | 20 Issuers |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Portfolio Value | $503,922,707 |
| JNJ Market Cap | $582.04 Billion |
| % of Market Cap | 0.087% |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: With a market capitalization of over $582 billion, a $504 million portfolio represents less than 0.1% of Johnson & Johnson's value. This filing is administrative and strategic rather than financially material to the parent company.
- Strategic Significance: The portfolio consists largely of strategic partnerships in the biotech space (e.g., Protagonist Therapeutics, Legend Biotech), reflecting J&J's R&D pipeline interests rather than pure financial speculation.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The value of assets reported is immaterial to JNJ's stock price. The filing serves as a transparency update regarding their venture capital arm's positions.
Volume & Sentiment
- Expected Volume Impact: None for JNJ. Potential minor volume impacts for the smaller held companies (e.g., Nanobiotix, MeiraGTx) due to confirmation of continued holding.
- Sentiment Indicator: Neutral. Confirms ongoing commitment to external innovation and partnerships.
Key Takeaways
- Strategic Focus: The portfolio is heavily weighted towards immunology and gene therapy, with Protagonist Therapeutics ($162M) and Nanobiotix ($106M) representing over 50% of the reported value.
- Administrative Update: This is a restatement (Amendment 1) for the period ending September 30, 2025, likely correcting clerical details from the original filing.
- No Market Signal: This filing does not represent a new insider buy/sell of JNJ stock, but rather a snapshot of JNJ's investments in other firms.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.